Tag Archives: ADC antibody-drug conjugates

Rayno Life Sciences: First Half Stock Performance Part I-ACHN, AMRI, VRTX

Biopharmaceutical Stocks Come Roaring Back After Q1 Correction Most Stocks Bottomed in April -We are Currently in Rally Mode The biotech sector is up 18% YTD as tracked by most popular ETFs (FBT,IBB,XBI). After a vicious sell-off from the February bubble the biotech sector bottomed in April and has climbed slowly t within 5% of  Q1 […]

Comments Off Continue Reading →

Biotech Recap On a Down Day

NASDAQ Off 0.8%  On Disappointing Economic Data and Spiking Crude  Islamic militants took major cities in Iraq  causing a spike in oil to $106. The energy sector rallied 0.7% with many smaller players soaring over 4%. The energy sector is very strong up 10% YTD. Retails sales rose less than expected with a 0.3% increase […]

Comments Off Continue Reading →

Risk Appetite Returns To Biotech With IBB Up Over 3%

Rayno Life Science Stocks -Green Screen Rules-NASDAQ (4168) Up 1.16% Speculative ETF XBI (134.50) up 4.69% and 7.88% over 5 days; 52 week high $172.52. ETF PBE ($40.85)  up over 3%. Momentum stocks are soaring but way off all time highs in February. Big Rayno Biopharma Movers: ACHN up 8%, ALKS up 3.4%, ARIA up […]

Comments Off Continue Reading →

Biotech Sell-Off Resumes: Caution Update 4/4

Update 4/4/14 Breach of Technicals-A Tad Below Early February Support Glut of Biotech IPOs Causing Indigestion? Momentum Days Are So Over NASDAQ Down 1.34% The volatile and speculative SPDR S&P Biotech XBI hit $136 in early trading down 2.28%.After a brief rally early this week to the $148 level volume picked up with sellers. The […]

Comments Off Continue Reading →

Biotech Bull Market: OK Let’s Just Call It A Bubble

Biotech May Be A Bubble-But What to Do? The blogosphere is trying to temper bullish sentiment with a lot of “bubble “talk even though the cable channels are still pumping biotech.  If you have been around biotech for 25 years especially during the last true bubble -1999 -you should be a little skeptical of the […]

Comments Off Continue Reading →

Two Emerging Growth Biotechnology Stocks Hit $10B+ Valuations: INCY, PCYC

With Updates Today  2/13/14   XBI at $157.8 Biotechnology Bubblet- How High Can These Stocks Run? We reviewed mid-cap biopharmaceutical valuation in early October as part of our overall market model for a sector that defies classical analysis. Two emerging growth stocks in our model focused in oncology have soared to the $10B market cap […]

Comments Off Continue Reading →